MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update
MaxCyte Inc provides cell-engineering platforms crucial for biotech and pharmaceutical companies developing cell therapies. The Nasdaq-listed company generates revenue from instrument sales, consumable cartridges, and long-term licensing deals, which include milestone payments and royalties. MaxCyte’s technology offers a scalable alternative to viral vectors, making it an important player in the growing cell and gene therapy market.
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools
MaxCyte Inc (MXCT) stock has shown recent volatility with increased trading volumes, as the company expands partnerships for its cell-engineering platforms. MaxCyte provides electroporation platforms for cell therapy, gene editing, and biopharma research, generating revenue through instrument sales, consumables, and licensing agreements with potential milestone payments and royalties. The company operates as a "picks-and-shovels" supplier for the growing cell and gene therapy industry, benefiting from the broad adoption of its technology rather than bearing the risks of individual drug development.
MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives
MaxCyte (MXCT) reported Q1 2026 revenue of US$9.7 million and a basic EPS loss of US$0.04, with the net loss narrowing compared to Q1 2025. Despite revenue forecasts and a long runway of SPL programs, analysts do not predict profitability within the next three years. The company currently trades at a 3.6x P/S, exceeding its peer average, while still incurring heavy losses, leading to skepticism about its valuation.
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday
This article highlights five stocks to watch on Wednesday, May 15, 2026, based on their upcoming earnings reports or recent financial results. Cisco Systems (CSCO), MaxCyte (MXCT), Alibaba Group (BABA), Nextpower Inc. (NXT), and Vishay Intertechnology (VSH) are featured, with details on expected earnings, revenue, and their after-hours stock performance.
River Global Investors Discloses Investment in MaxCyte with 6.1% Stake
River Global Investors LLP has disclosed a 6.095% stake in MAXCYTE, INC. after purchasing shares on the open market, crossing the 5% reporting threshold. The London-based firm acquired 650,000 shares at approximately $1.11 each on May 13, 2026, for funds it manages. No plans for board seats or significant changes at MaxCyte were indicated.
River Global Investors builds 6.1% MaxCyte (MXCT) position with 6.53M shares
River Global Investors LLP has disclosed a 6.1% stake in MaxCyte, Inc. (MXCT), equating to 6,529,027 equity shares. The firm holds sole voting and dispositive power over these shares, which were acquired using investment capital through ordinary open-market transactions, including recent purchases on May 13, 2026. This indicates River Global's role as a financial investor rather than a strategic partner in MaxCyte.
Stock Market Today: Dow Jones Futures Fall, S&P 500 Gains As Trump Takes Big Tech Leaders To China—Nvidia, Nextpower, Red Cat In Focus
U.S. stock futures showed mixed performance, with Dow Jones futures falling while S&P 500 and Nasdaq 100 rose, following President Donald Trump's visit to China with tech leaders like Nvidia CEO Jensen Huang. Several companies, including Nextpower, MaxCyte, and Taiwan Semiconductor Manufacturing, saw significant stock movement based on earnings and strategic announcements, while Red Cat Holdings plunged after a public offering. Professor Jeremy Siegel offered an optimistic market outlook, citing resilient labor data and the AI boom as key drivers, despite elevated S&P 500 valuations.
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue dips as expenses fall
MaxCyte (NASDAQ: MXCT) reported its Q1 2026 financial results, showing a decrease in revenue to $9.7 million from $10.4 million in the prior year, though the net loss narrowed significantly to $4.8 million from $10.3 million due to reduced operating expenses. The decline in revenue was attributed to weaker core product and license sales, partially offset by an increase in Strategic Platform License milestones and royalties. The company maintained a high gross margin of 84% and expects its existing cash and investments to fund operations for at least the next 12 months.
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
MaxCyte's Q1 2026 earnings call revealed a company with strong cash reserves and reduced operating expenses, despite a sharp decline in core revenue. Management anticipates a recovery in the latter half of the year, driven by new product adoption and expanding strategic platform license (SPL) partnerships, as the company navigates a transitional period with external headwinds affecting immediate growth.
MaxCyte Q1 Earnings Call Highlights
MaxCyte reported a 7% decrease in Q1 2026 revenue to $9.7 million, with core revenue down 25% due to discontinued SPL programs and customer inventory management. Despite the decline, the company reiterated its full-year 2026 revenue guidance of $30 million to $32 million, anticipating a stronger second half driven by its ExPERT DTx product and easier comparisons. MaxCyte also highlighted progress in its SPL portfolio, CASGEVY royalties, SeQure business, and announced a $10 million share buyback, ending the quarter with $147.7 million in cash and no debt.
Press Release: MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MaxCyte has reported its first-quarter 2026 financial results, which include revenue figures for its Core Business and SPL Program. The company has also reaffirmed its financial guidance for the full year 2026, indicating confidence in its projected performance.
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue
MaxCyte (MXCT) exceeded first-quarter 2026 forecasts, reporting an EPS of -$0.04 against an expected -$0.08, and revenue of $9.7 million, significantly higher than the $7.3 million forecast. The company's stock rose 2.2% in aftermarket trading, driven by strong SPL program-related revenue growth despite an overall 7% decrease in total revenue year-over-year. MaxCyte reiterated its full-year 2026 guidance, expecting total revenue between $30 million and $32 million, and announced a $10 million share repurchase program, underscoring confidence in its long-term value and strategic investments.
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript
MaxCyte, Inc. (NASDAQ:MXCT) reported Q1 2026 earnings, discussing total revenue of $9.7 million, including $6.2 million from core activities and $3.4 million from milestone and royalty revenues. The company reiterated its full-year 2026 revenue guidance and announced a $10 million share repurchase program, reflecting confidence in its long-term value and strengthened financial position. Discussions also covered the progress of their ExPERT DTX product, SeQure assays, and the evolving landscape of cell and gene therapy, with a focus on later-stage clinical programs.
MaxCyte Q1 Earnings Call Highlights
MaxCyte reported a 7% decrease in Q1 2026 revenue to $9.7 million, with core revenue down 25% due to discontinued SPL programs and customer inventory management. Despite the decline, the company expects core revenue growth in the second half of 2026, driven by its new ExPERT DTx product and easier year-over-year comparisons, reiterating its full-year revenue guidance of $30 million to $32 million. MaxCyte also highlighted its SPL portfolio, progress with CASGEVY royalties, growth in its SeQure business, and cost reductions leading to a board-authorized share repurchase program.
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2026 Earnings Conference
This document is an earnings call summary for MaxCyte (MXCT.US) for its Q1 2026 earnings conference. It provides details regarding the company's financial performance and operational highlights for the quarter.
MaxCyte Q1 Earnings Call Highlights
MaxCyte reported a 7% decrease in Q1 2026 total revenue to $9.7 million, with core revenue down 25% due to discontinued SPL programs and customer inventory management. Despite the decline, the company reiterated its full-year guidance, expecting second-half core revenue growth fueled by its ExPERT DTx product and easier year-over-year comparisons. MaxCyte highlighted its SPL portfolio, progress with CASGEVY royalties, growth in its SeQure business, and cost-cutting measures, alongside a new $10 million share repurchase authorization.
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
MaxCyte (MXCT) announced its Q1 2026 results, reporting a 7% year-on-year revenue decline to $9.7 million, although its net loss and EBITDA deficit significantly decreased due to higher SPL revenue and lower operating expenses. The company reaffirmed its full-year 2026 revenue guidance of $30 million to $32 million and authorized a $10 million share repurchase program, signaling confidence in its strategy despite current financial performance. TipRanks' AI Analyst, Spark, rates MXCT as Neutral, citing weak financial performance and near-term revenue pressure, but acknowledges the company's strong cash position.
MaxCyte posts $4.8M loss, still lines up $10M stock buyback
MaxCyte (NASDAQ: MXCT) reported a Q1 2026 net loss of $4.8 million, an improvement from $10.3 million in Q1 2025, but total revenue decreased by 7% year-over-year to $9.7 million. Despite the revenue decline, the company reiterated its full-year 2026 revenue guidance of $30-32 million and authorized a $10 million share repurchase program, signaling confidence in its long-term strategy and financial stability. The improvement in net loss was partly due to reduced operating expenses and an increase in Strategic Platform License (SPL) revenue.
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback
MaxCyte, Inc. reported its Q1 2026 financial results, with total revenue of $9.7 million, a 7% decrease year-over-year, but significantly narrowed its net loss to $4.8 million from $10.3 million in Q1 2025 due to reduced operating expenses. The company reiterated its full-year 2026 revenue guidance of $30–32 million and announced a $10 million share repurchase program, signaling confidence in its strategy and long-term value. Key figures include core revenue of $6.2 million and Strategic Platform License (SPL) program-related revenue of $3.4 million, with a strong balance sheet showing $147.7 million in cash and investments.
MaxCyte (Nasdaq:MXCT) - Stock Analysis
This article provides a detailed stock analysis of MaxCyte (Nasdaq:MXCT), a life sciences company, highlighting its current undervaluation by analysts despite recent stock performance. It outlines various financial metrics, future growth prospects, past performance, recent news including executive appointments, earnings guidance, and its continuous effort to maintain Nasdaq listing requirements. The analysis also covers analyst price targets and significant insider transactions, suggesting potential investment opportunities.
SEC Form DEFA14A filed by MaxCyte Inc.
MaxCyte Inc. (MXCT) has filed an SEC Form DEFA14A, as reported by Quantisnow. The company is also scheduled to release its first-quarter 2026 financial results on May 12, 2026. This filing follows several recent insider transactions and analyst updates for MaxCyte.
MaxCyte (MXCT) price target decreased by 11.67% to 4.33
The article reports that the price target for MaxCyte (MXCT) has been decreased by 11.67%, setting the new target at 4.33. This indicates a revised outlook from analysts regarding the company's future stock performance.
[ARS] MAXCYTE, INC. SEC Filing
This article reports on MAXCYTE, INC.'s (MXCT) SEC filing of Form ARS on April 29, 2026, at 04:48 PM. It notes the low impact and neutral sentiment of the filing. The article also provides essential company information, including market cap, industry, and recent news and SEC filings related to MXCT.
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
MaxCyte, Inc. (NASDAQ: MXCT) announced that it will release its first quarter 2026 financial results after the U.S. market close on Tuesday, May 12, 2026. The company will also host a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are advised to register online in advance to listen to the call, with a live and archived webcast available on MaxCyte's investor relations website.
Directors and auditor on ballot at MaxCyte (NASDAQ: MXCT) 2026 meeting
MaxCyte, Inc. (NASDAQ: MXCT) will hold its 2026 annual meeting on June 17, 2026, where stockholders will vote on electing three Class II directors—Patrick Balthrop, Cynthia Collins, and Stanley Erck—to serve until the 2029 annual meeting. Additionally, stockholders will ratify CohnReznick LLP as the independent auditor for the fiscal year ending December 31, 2026. The company's CEO, Maher Masoud, received $2,687,657 in total compensation for 2025, and major shareholders include Capricorn Fund Managers, BlackRock, and River Global Investors.
MaxCyte schedules May 12 earnings release, 4:30 p.m. call
MaxCyte (NASDAQ: MXCT) will release its first-quarter 2026 financial results after the U.S. market closes on May 12, 2026. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results, and investors are required to register online in advance to participate. A live and archived webcast of the event will also be available on the investor relations section of MaxCyte's website.
MaxCyte (MXCT) price target decreased by 14.88% to 4.90
The article reports that the price target for MaxCyte (MXCT) has been reduced by 14.88%, lowering it to 4.90. This indicates a revised outlook on the company's stock valuation.
MaxCyte announces 34% workforce reduction to cut costs
MaxCyte has announced a significant 34% reduction in its workforce as part of a cost-cutting initiative. This move aims to streamline operations and improve the company's financial efficiency. The company is taking these measures to navigate economic challenges and optimize its business model.
MaxCyte announces 34% workforce reduction to cut costs
MaxCyte has announced a significant restructuring, including a 34% reduction in its workforce, to cut costs and align its resources with strategic priorities. The company projects these measures will result in annual savings of approximately $18-20 million, significantly improving its financial outlook. This strategic adjustment aims to streamline operations and enhance focus on its core business.
MaxCyte sees Q4 core revenue between $6.6M and $6.7M
MaxCyte announced preliminary core revenue guidance for the fourth quarter, expecting it to fall between $6.6 million and $6.7 million. This announcement was made during their presentation at the J.P. Morgan Healthcare Conference, indicating their financial performance and outlook for the period. The range provides an early look at the company's Q4 earnings.
MaxCyte (MXCT) CFO receives 187,500 restricted stock units in equity grant
MaxCyte, Inc.'s Chief Financial Officer, Parmeet Ahuja, has been granted 187,500 restricted stock units (RSUs) as an equity award. These RSUs, which represent a contingent right to receive one share of common stock each, will vest over time, with 25% vesting on March 30, 2027, and the remainder in three equal annual installments, subject to Ahuja's continued employment. Following this grant, Ahuja directly holds 187,500 shares of common stock.
Earnings Call Summary | MaxCyte(MXCT.US) Q4 2025 Earnings Conference
MaxCyte (MXCT.US) reported a revenue decline in Q4 and full year 2025, falling to $33 million from $38.6 million in 2024, attributed to decreases in both core and SPL program-related revenue. Despite launching a new product (ExPERT DTx) and integrating SeQure DX, the company anticipates total revenue for 2026 to be between $30 million and $32 million, facing headwinds from customer program rationalizations and biotech funding variabilities.
MAXCYTE (MXCT) CFO Parmeet Ahuja named reporting insider in Form 3
MAXCYTE, INC. (MXCT) CFO Parmeet Ahuja has been named a reporting insider through a Form 3 filing. This filing formally establishes Ahuja's obligation to report future holdings or transactions in MAXCYTE securities, but the filing itself does not indicate any current transactions or changes in share ownership. The Form 3 is a routine initial disclosure for individuals becoming company insiders, such as CFOs.
MaxCyte (MXCT) CFO awarded 375,000 employee stock options at $0.6762
MaxCyte's CFO, Parmeet Ahuja, was granted 375,000 employee stock options with an exercise price of $0.6762 per share, expiring on March 29, 2036. The options will vest over time, with 25% vesting on March 30, 2027, and the remaining 75% in 36 equal monthly installments, contingent on continued service. This grant brings Ahuja's direct holdings to 375,000 stock options.
Mirabella exit leaves MaxCyte (NASDAQ: MXCT) ownership at 0% after Jan 5, 2026
Mirabella Financial Services LLP has reported to MaxCyte (NASDAQ: MXCT) via a SCHEDULE 13G/A filing that it no longer holds any shares of the company. Mirabella ceased acting as the Investment Manager for Blue Riband Fund LP on January 5, 2026, thereby losing all discretion over voting and dispositive power of the shares. The filing, signed on April 10, 2026, indicates zero beneficial ownership and zero percent of class for MaxCyte's common stock.
MaxCyte (MXCT) price target decreased by 11.67% to 4.33
The article reports that the price target for MaxCyte (MXCT) has been reduced by 11.67%, setting the new target at 4.33. This indicates a revised outlook on the company's stock valuation.
MaxCyte receives Nasdaq notice for non-compliance with minimum bid price
MaxCyte (NASDAQ:MXCT) has received a notice from Nasdaq for failing to meet the minimum bid price requirement of $1.00 per share for 30 consecutive trading days. The company has 180 calendar days, until September 14, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive trading days. Failure to comply could lead to delisting, though MaxCyte may be eligible for an extension if it transfers to the Nasdaq Capital Market.
MXCT PE Ratio & Valuation, Is MXCT Overvalued
MaxCyte Inc (MXCT) is currently considered undervalued, with a fair price estimated between $2.44 and $7.04 compared to its current price of $0.75. Its Price-to-Book ratio is 0.47, significantly lower than its historical averages. However, its P/S ratio of 2.06 is considerably above the industry average, and its Forward Free Cash Flow yield is negative.
MaxCyte (MXCT) price target decreased by 14.88% to 4.90
This article reports that MaxCyte (MXCT)'s price target has been decreased by 14.88%, bringing it down to 4.90. The content provided is minimal, offering only this specific financial update.
MaxCyte (MXCT) price target decreased by 14.88% to 4.90
This article reports that MaxCyte (MXCT) has had its price target decreased by 14.88%, bringing it down to 4.90. The brief update does not provide further details or analysis regarding the adjustment.
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, Inc. announced inducement awards granted to Parmeet Ahuja as he joins the company as Chief Financial Officer. These awards, consisting of stock options and restricted stock units, were issued in accordance with Nasdaq Listing Rule 5635(c)(4). The grants are part of his employment agreement with vesting schedules tied to continuous service.
MaxCyte (MXCT) CEO awarded 600,000 options and 300,000 RSUs
MaxCyte (MXCT) CEO Masoud Maher was granted an equity compensation package including 600,000 stock options and 300,000 restricted stock units (RSUs). The stock options have an exercise price of $0.684 per share and expire in 2036, with vesting tied to continued service. The RSUs also vest over several years, contingent on his employment with the company.
New MaxCyte CFO gets 562,500-share inducement award under Nasdaq rule
MaxCyte has granted its new Chief Financial Officer, Parmeet Ahuja, inducement awards totaling 562,500 shares, comprising 375,000 stock options and 187,500 restricted stock units (RSUs). These awards, granted under Nasdaq Listing Rule 5635(c)(4), are designed to incentivize Mr. Ahuja and will vest over four years, subject to his continued employment. The stock options have an exercise price matching the closing price of MaxCyte's common stock on March 30, 2026, at $0.676.
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, Inc. announced inducement awards granted to Parmeet Ahuja upon his appointment as Chief Financial Officer. These awards, consisting of stock options for 375,000 shares and a restricted stock unit award for 187,500 shares, were made under the company's 2026 Inducement Plan. The grants are intended to incentivize Mr. Ahuja's employment and vest over four years, subject to his continuous service.
MaxCyte (NASDAQ:MXCT) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen has upgraded MaxCyte (NASDAQ:MXCT) from a "sell" to a "hold" rating, contributing to a consensus "Hold" rating among analysts with a target price of $5.50. Despite beating EPS estimates in its latest quarter, MaxCyte missed revenue expectations and exhibits negative net margin and return on equity. The stock is currently trading significantly below its 200-day moving average and one-year high.
MaxCyte appoints Parmeet Ahuja as CFO, succeeding Douglas Swirsky
MaxCyte has announced the appointment of Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja will succeed Douglas Swirsky in the role. Ahuja brings over 20 years of finance leadership experience, including previous roles as VP of Investor Relations and VP of FP&A at Agilent.
MaxCyte, Inc. (MXCT) reports Q4 loss, misses revenue estimates
MaxCyte, Inc. (MXCT) announced its Q4 earnings, reporting a loss per share of $0.21, which was worse than analysts' expectations of a $0.09 loss. The company also missed revenue estimates, reporting $9.74 million against an expected $10.60 million. This performance contrasts with the previous year's Q4 loss of $0.11 per share and higher revenues.
MaxCyte Appoints New Chief Financial Officer Ahuja
MaxCyte has appointed Parmeet Ahuja as its new Chief Financial Officer, effective March 30, 2026. Ahuja brings over two decades of financial experience from Agilent Technologies, signaling MaxCyte's focus on strengthening its financial operations and investor relations. His compensation package includes a $450,000 base salary, a target cash bonus, and substantial equity awards, with the company's stock currently holding a "Sell" recommendation from Spark, TipRanks’ AI Analyst, due to weak financial performance despite a strong cash balance.
New MaxCyte (NASDAQ: MXCT) CFO Parmeet Ahuja joins from Agilent
MaxCyte, Inc. has announced the appointment of Parmeet Ahuja as its new Chief Financial Officer and principal accounting officer, effective March 30, 2026. Ahuja brings over two decades of financial leadership experience from Agilent Technologies. His compensation includes an annual base salary of $450,000, a target cash bonus, and significant equity awards, with a severance agreement also in place.
Vanguard disaggregates holdings; reports 0% stake in MaxCyte (MXCT)
The Vanguard Group has filed an amended Schedule 13G/A report indicating zero beneficial ownership of MaxCyte Inc. common stock. This change, effective January 12, 2026, is due to an internal realignment where certain Vanguard subsidiaries will now report their holdings separately. The filing confirms 0 shares (0%) beneficially owned by The Vanguard Group itself, with no sole or shared voting or dispositive power over MaxCyte stock.
